Hematological findings and complications of COVID‐19
暂无分享,去创建一个
Theodora Psaltopoulou | M. Dimopoulos | T. Psaltopoulou | E. Kastritis | E. Terpos | Efstathios Kastritis | Evangelos Terpos | I. Elalamy | I. Ntanasis-Stathopoulos | Ismail Elalamy | Meletios A Dimopoulos | G. Gerotziafas | T. Sergentanis | Marianna Politou | Ioannis Ntanasis-Stathopoulos | Theodoros N Sergentanis | Grigoris Gerotziafas | M. Politou | I. Ntanasis‐Stathopoulos
[1] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[2] Sharukh Lokhandwala,et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.
[3] J. Low,et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.
[4] W. Boersma,et al. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. , 2012, European journal of internal medicine.
[5] Wei Liu,et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study , 2020, Chinese medical journal.
[6] J. Szer,et al. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage , 2020, Bone Marrow Transplantation.
[7] Jiann-Jou Yang,et al. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. , 2002, Journal of immunology.
[8] G. B. Tan,et al. Hematologic parameters in patients with COVID‐19 infection , 2020, American journal of hematology.
[9] S. Aggarwal,et al. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. , 1999, Journal of immunology.
[10] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[11] G. Guyatt,et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. , 2018, Blood advances.
[12] Dengju Li,et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[13] Mohammad Madjid,et al. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.
[14] J. Patel,et al. COVID-19 and the liver: little cause for concern , 2020, The Lancet Gastroenterology & Hepatology.
[15] Mario Plebani,et al. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.
[16] Peter Cameron,et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.
[17] Tao Guo,et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.
[18] Jiann-Jou Yang,et al. IL-19 Induces Production of IL-6 and TNF-α and Results in Cell Apoptosis Through TNF-α1 , 2002, The Journal of Immunology.
[19] Yong-tang Zheng,et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[20] D. Lillicrap. Disseminated intravascular coagulation in patients with 2019‐nCoV pneumonia , 2020, Journal of Thrombosis and Haemostasis.
[21] Xiao Chen,et al. Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19 , 2020, Journal of medical virology.
[22] Yuanliang Xie,et al. Findings of Acute Pulmonary Embolism in COVID-19 Patients , 2020 .
[23] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[24] Taiwen Li,et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa , 2020, International Journal of Oral Science.
[25] G. Lippi,et al. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.
[26] Gregor Rothe,et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.
[27] A. Earnest,et al. Haematological parameters in severe acute respiratory syndrome , 2005, Clinical and laboratory haematology.
[28] A. Falanga,et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[29] Qi Wang,et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.
[30] Li Tan,et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.
[31] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[32] Elie A Akl,et al. Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .
[33] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[34] Aman Sharma,et al. High Producer Haplotype (CAG) of -863C/A, -308G/A and -238G/A Polymorphisms in the Promoter Region of TNF-α Gene Associate with Enhanced Apoptosis of Lymphocytes in HIV-1 Subtype C Infected Individuals from North India , 2014, PloS one.
[35] Giuseppe Biondi-Zoccai,et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic , 2020, Journal of the American College of Cardiology.
[36] D. Brodie,et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic , 2020 .
[37] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[38] J. Thachil,et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines , 2013, Journal of thrombosis and haemostasis : JTH.
[39] G. Raskob,et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis , 2020, TH Open.
[40] W. Gong,et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.
[41] Chuan Qin,et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] K. To,et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] A. Ravaud,et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection , 2020, The Lancet Oncology.
[44] Mario Plebani,et al. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis , 2020, Clinica Chimica Acta.
[45] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[46] Dengju Li,et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.
[47] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[48] R. Liu,et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection , 2020, Clinical chemistry and laboratory medicine.
[49] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[50] Hongzhou Lu,et al. Clinical observation and management of COVID-19 patients , 2020, Emerging microbes & infections.
[51] T. West,et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.
[52] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[53] E. Staley,et al. Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID‐19) pandemic affecting Washington State , 2020, Transfusion.